Parts of the motor circuits

Similar documents
Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Parkinson s Disease. Sirilak yimcharoen

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

Clinical Features and Treatment of Parkinson s Disease

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

Parkinson s Disease Update

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Identification number: TÁMOP /1/A

Optimizing Clinical Communication in Parkinson s Disease:

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

Objectives. Distinguishing Parkinson s disease from other parkinsonian and tremor syndromes. Characteristics. Basal Ganglia Structures

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Parkinson s Disease Current Treatment Options

III./3.1. Movement disorders with akinetic rigid symptoms

Treatment of Parkinson s Disease: Present and Future

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

10th Medicine Review Course st July Prakash Kumar

Differential Diagnosis of Hypokinetic Movement Disorders

Disorders of Movement M A R T I N H A R L E Y N E U R O L O G Y

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE

Basal ganglia Sujata Sofat, class of 2009

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor

8/28/2017. Behind the Scenes of Parkinson s Disease

Semivoluntary movement (=unvoluntary)

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

Evaluation and Management of Parkinson s Disease in the Older Patient

Movement Disorders: A Brief Overview

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Parkinson s Disease. Gillian Sare

Atypical parkinsonism

The motor regulator. 1) Basal ganglia/nucleus

The Shaking Palsy of 1817

VL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements

First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

14 : 4. D Nagaraja, Pramod Kumar Pal, N Karthik, Bangalore. Abstract:

Parkinsonism. Parkinsonism. James Parkinson A syndrome. Causes of Parkinsonism

Pal Riba, M.D., Ph.D. Department of Pharmacology and Pharmacotherapy Semmelweis University, Budapest, Hungary November 7, 2017

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

Movement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types

Update on Parkinson s disease and other Movement Disorders October 2018

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Faculty. Joseph Friedman, MD

Parkinson disease What is Parkinson's disease? What causes the disease?

Drugs Affecting the Central Nervous System

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

COGNITIVE SCIENCE 107A. Motor Systems: Basal Ganglia. Jaime A. Pineda, Ph.D.

Parkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015

Evaluation of Parkinson s Patients and Primary Care Providers

With Time, The Pathology of PD Spreads Throughout the Brain

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

EBM Parkinson s Diseases

Parkinson s Disease and other related movement disorders a video guide to diagnosis

MULTI SYSTEM ATROPHY: REPORT OF TWO CASES Dipu Bhuyan 1, Rohit Kr. Chandak 2, Pankaj Kr. Patel 3, Sushant Agarwal 4, Debjanee Phukan 5

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)

Parkinson Disease. What causes the disease? Parkinson's disease occurs when nerve cells, or neurons, in an area of the brain known as the substantia

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

Moving fast or moving slow: an overview of Movement Disorders

Dr Barry Snow. Neurologist Auckland District Health Board

Extrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010

Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.

Parkinson's Disease. Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology

The Latest Research in Parkinson s Disease. Lawrence Elmer, MD, PhD Professor, Dept. of Neurology University of Toledo

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

A. General features of the basal ganglia, one of our 3 major motor control centers:

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Medications used to treat Parkinson s disease

Parkinson's Disease KP Update

A. General features of the basal ganglia, one of our 3 major motor control centers:

Lecture 42: Final Review. Martin Wessendorf, Ph.D.

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

Chapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.

A Parkinson s Disease and related disorders

Professor Tim Anderson

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

PARKINSON S MEDICATION

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD

PD: Key Treatment Considerations

Surgical Treatment: Patient Edition

The PSP Association. Presentation on the symptoms, care and support of patients with PSP.

EMERGING TREATMENTS FOR PARKINSON S DISEASE

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit

Clinical picture of Parkinson s disease: Mean age of onset- is about 55 yrs. Juvenile Parkinsonism is also known.

symptoms of Parkinson s disease EXCEPT.

Deep Brain Stimulation: Indications and Ethical Applications

PARKINSON S DISEASE: current aspects of ETIOLOGY, DIAGNOSIS and TREATMENT. Dilek Ince Gunal, MD Assoc. Prof

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Basal Ganglia. Today s lecture is about Basal Ganglia and it covers:

UNDERSTANDING PARKINSON S DISEASE

Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson s Disease

Transcranial sonography in movement disorders

Transcription:

MOVEMENT DISORDERS

Parts of the motor circuits cortical centers: there are centers in all the cortical lobes subcortical centers: caudate nucleus putamen pallidum subthalamical nucleus (Luys) nucleus ruber substantia nigra striatum nucleus lentiformis

There are two main clinically different groups: hypokinetic-hypertonic (rigid) hyperkinetic-hypotonic

hypokinetic-hypertonic (rigid) syndrome Parkinson s disease, Parkinsonian syndromes

The etiology of the Parkinsonism primer, idiopathic form: Parkinson s disease - the second most frequent progressive neurodegenerative disease - the prevalence is 1% in the 65 year old population and it increases to 4-5% in the 85 year old population - it is most frequently sporadic - approximately 10% of the cases are familiar (there are 16 indentified genes, wich cause autosomal dominant, or recessive forms of Parkinson s disease)

The etiology of the Parkinsonian syndromes symptomatic: Parkinson s syndrome trauma tumor inflammation (encephalitis) stroke (ischemic, hemorrhagic) toxic agents (CO, neuroleptic drugs)

The etiology of the Parkinsonian syndromes Parkinson plus diseases - Synucleopathies: Multi System Atrophy (MSA) - Taupathies (abnormaly fosforilated Tau protein): Progresive Supranuclear Palsy (PSP)= Steel-Richardson-Olszewski sy. Corticobasal Degeneration

The neuropathologic basis of Parkinson s disease degeneration of the substantia nigra and the striatum (Lewy bodies- citoplasmatic protein aggregations) disintegration of the dopamin-acetilcholin balance in the central nervous system decrease of the dopamin level and cholinergic dominance

the main motor symptoms of Parkinsonism rigidity tremor hypo-, and bradykinesis postural instability

rigidity the tone of the agonist és antagonist (flexor and extensor) muscles increases paralelly the trunk and the extremities are in semiflected position during passive movement of the extremities we can feel permanent resistance (cogwheel phenomenon) very often assimetrical distribution

tremor the agonistic and antagonistic (flexor és extensor) muscles contract with rhytmic, 6-8/sec. frequency the tremor is most prominent in resting position, the stress could provoke it the intended movements decrease the tremor and it is stopped during sleep very often assimetrical distribution

hypo-, and bradykinesis movements and walking become slow, sluggish and difficult shuffling gait with decreased excursion of legs difficulties in turning freezing: sudden stop in walking and movements

other signs (motor) on-off phenomenon retropulsion hypomimia, or blank face monotonous speech micrographia

hyposmia, hypogeusia other signs (non motor) vegetative problems: orthostatic hypotension, incontinence, impotence, hyperperspiration gastrointestinal problems :swallowing difficulty, hypersalivation, gastroparesis, constipation pain and other sensory disturbances depression sleep disorders

Parkinson plus diseases Multi System Atrophy (MSA) - Papp-Lantos disease the stages of the disease: striato-nigral degeneration olivo-ponto-cerebellar atrophy Shy-Drager syndrome no, or mild asimmetricity in the parkinsonic signs early falls down autonomic dysfunctions (orthostatic hypotension, impotence, incontinence, respiratory stridor) dropped head pyramidal signs, cerebellar signs no, or just partial respons to levodopa therapy

Parkinson plus diseases Progresive Supranuclear Palsy (PSP)- Steel-Richardson-Olszewski sy. postural instability, early falls down, axial rigidity, freezing supranuclear gaze paresis (predominantly vertical) downwards gaze! frontal lobe signs (primitive reflexes, apathy, frontal demencia)

the Parkinsonian crisis could be life complete immobility aphagia and anarthria extreme rigidity fever threatening!! cardiovascular inssufficiency bedsores, pneumonia, deep vein thrombosis, lung embolism

treatment DRUGS MAO B inhibitors (selegilin, rasagiline) Amantadin (PK Merz) Dopamin agonists (ergotamine type:bromocriptin, non ergotamin type: ropinirole, pramipexole, rotigotine, apomorphine) L-DOPA substitution (L-DOPA+DOPA decarboxilase inhibitor) per os and intrajejunal infusion DUODOPA COMT inhibitors (entacapone) L-DOPA+DOPA decarboxilase inhibitor+ COMT inhibitor anticholinergic drugs (metixene, procyclidine)

treatment SURGICAL (just in severe cases, when the antiparkinsonian drugs are uneffective) deep brain stimulation DBS (uni-, or bilateral) target zones: STN, pallidum, thalamus VIM nucleus thalamotomy, pallidotomy (uni-, or bilateral) neurotransplantation (inplantation of fetal mesencephalic cells into the caudat nucleus and putamen region)

treatment physicotherapy (training, special exercises) psychotherapy